As of April 26, 2023, roughly 367 million Pfizer-BioNTech COVID-19 vaccine doses had been administered in the United States. This statistic shows the number of COVID-19 vaccinations administered in the United States as of April 26, 2023, by manufacturer.

COVID-19 Vaccines Market Outlook

According to our latest research, the global COVID-19 vaccines market size stood at USD 34.2 billion in 2024, reflecting a significant contraction from the pandemic’s peak but still underscoring the ongoing demand for booster shots, variant-specific formulations, and immunization programs. The market is expected to reach USD 14.7 billion by 2033, registering a compound annual growth rate (CAGR) of 9.8% over the forecast period. This trajectory is driven by persistent global immunization efforts, the emergence of new SARS-CoV-2 variants, and the integration of COVID-19 vaccines into routine vaccination schedules.

The primary growth factor for the COVID-19 vaccines market is the continued evolution of the SARS-CoV-2 virus, leading to the emergence of new variants. These variants often exhibit mutations that may partially evade immunity conferred by previous infection or vaccination, necessitating the development and deployment of updated vaccine formulations. Pharmaceutical companies are investing in next-generation vaccines, including multivalent and pan-coronavirus candidates, to address these challenges. Governments and health organizations remain vigilant, maintaining stockpiles and rolling out booster campaigns, especially for high-risk populations such as the elderly and immunocompromised. The integration of COVID-19 vaccines with seasonal influenza programs is also being explored, potentially driving market growth through combined immunization initiatives.

Another crucial driver is the growing emphasis on equitable vaccine access, particularly in low- and middle-income countries. International collaborations, such as COVAX and bilateral donation agreements, have played a vital role in expanding vaccine reach beyond high-income nations. As the acute phase of the pandemic subsides, there is a strategic shift towards sustained immunization efforts, with many countries incorporating COVID-19 vaccines into their national immunization schedules. This long-term approach is expected to stabilize demand and support market growth, albeit at a lower volume compared to the pandemic’s initial years. Additionally, the development of pediatric and variant-adapted vaccines is broadening the addressable market, ensuring ongoing relevance for manufacturers.

Technological advancements in vaccine platforms, particularly mRNA and protein subunit technologies, are reshaping the market landscape. The success of mRNA vaccines has spurred further research into their application for other infectious diseases, creating a pipeline of innovative products. These platforms offer advantages such as rapid adaptability to emerging variants and scalable manufacturing, making them attractive for both public health authorities and commercial stakeholders. The competitive environment is also fostering partnerships between pharmaceutical companies, biotechnology firms, and academic institutions to accelerate research and development. Such collaborations are expected to yield more effective and durable vaccines, further propelling the market’s evolution.

From a regional perspective, North America and Europe continue to lead the market in terms of revenue, owing to robust healthcare infrastructure, high vaccination coverage, and proactive government policies. The Asia Pacific region is witnessing the fastest growth, driven by large population bases, increasing healthcare investments, and expanding immunization programs. Latin America and the Middle East & Africa are gradually improving their vaccination rates, supported by international aid and local manufacturing initiatives. The regional dynamics are influenced by factors such as regulatory approvals, supply chain logistics, and public acceptance of vaccines, which collectively shape the market’s trajectory across different geographies.

Vaccine Type Analysis

The COVID-19 vaccines market is segmented by vaccine type into mRNA vaccines, viral vector vaccines, protein subunit vaccines, inacti

According to a forecast as of March, BioNTech's and Pfizer's vaccine against COVID-19 could generate sales revenues of nearly 22 billion U.S. dollars during 2021. The BioNTech/Pfizer vaccine was the first COVID-19 vaccine to be widely approved and used. German biotech company BioNTech saw a 156 percent growth in its shares in the last 12 months as of March 2021.

Will Moderna be the big winner? Moderna is expected to be the company with the largest sales revenues from a COVID-19 vaccine. Forecasts predict that the company will make around 43 billion U.S. dollars in sales through its vaccine. Interestingly, Moderna was established in 2010 and had never made profit before the pandemic. Thus, the development of the covid vaccine based on the latest mRNA technology will mark a definitive breakthrough for the Massachusetts-based biotech company. Moderna received significant funding through taxpayer money as well as help in research and development from the National Institutes of Health.

Vaccine pricing in a pandemic Drug pricing is always a big issue and this was also the case with COVID-19 vaccines. While some companies, like AstraZeneca, stated early on that prices for the vaccine will be on a non-profit base at least as long as the pandemic is ongoing, others took a more profit-oriented approach. However, even these companies state that their current prices are low special prices, taking into account urgent public health interests, which normally would be much higher. According to several projections, COVID-19 drugs and vaccines could establish a market worth some 40 billion U.S. dollars annually.

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines stood at approximately USD 45 billion in 2023 and is projected to reach around USD 78 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This substantial growth is primarily driven by continuous advancements in vaccine technology, increasing global vaccination drives, and the emergence of new variants necessitating booster doses.

One of the primary growth factors for the approved COVID-19 vaccines market is the ongoing need for booster vaccinations. As new variants of the virus emerge, vaccine manufacturers are continuously enhancing existing vaccines to tackle these variants effectively. This continuous innovation ensures sustained demand for updated vaccines, thereby propelling market growth. Additionally, governments worldwide are investing heavily in vaccination programs to achieve herd immunity, further boosting market size. Initiatives like COVAX, which aim to provide equitable vaccine access, are also significant contributors to market expansion.

Another crucial factor driving market growth is the increased awareness and acceptance of vaccines among the global population. Intensive public health campaigns and educational movements have led to a higher acceptance rate of vaccines, reducing vaccine hesitancy. This trend is particularly significant in emerging economies where initial vaccine skepticism was high. The successful roll-out of initial vaccine doses has built public confidence, thereby increasing the uptake of booster doses and new vaccine variants.

The collaboration between pharmaceutical companies and governments has also played a pivotal role in the growth of the COVID-19 vaccines market. Strategic partnerships for vaccine production, distribution, and administration have streamlined the supply chain, making vaccines more accessible to the public. These collaborations have also facilitated bulk purchasing agreements, which have provided cost advantages and enhanced market penetration across various regions. Moreover, the establishment of new manufacturing facilities and the expansion of existing ones have significantly accelerated vaccine production capabilities.

The development of the COVID-19 RNA Vaccine has been a groundbreaking advancement in the fight against the pandemic. Unlike traditional vaccines, RNA vaccines work by introducing a small piece of genetic material from the virus into the body, prompting an immune response without using a live virus. This innovative approach has allowed for rapid development and deployment, significantly contributing to the global vaccination efforts. The flexibility of RNA technology also enables quick updates to the vaccine to address new variants, ensuring continued protection as the virus evolves. This adaptability has made RNA vaccines a crucial tool in achieving widespread immunity and controlling the spread of COVID-19.

Regionally, North America leads the market due to its advanced healthcare infrastructure and early adoption of vaccination programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK. The Asia Pacific region is witnessing rapid growth, driven by substantial investments in healthcare infrastructure and large-scale vaccination drives in countries like India and China. Meanwhile, Latin America and the Middle East & Africa are gradually catching up, supported by international aid and improving healthcare systems. The regional diversity ensures a balanced growth outlook for the global market.

Vaccine Type Analysis

The market for approved COVID-19 vaccines is segmented into various types, including mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant traction due to their high efficacy rates and the rapid speed of development. The flexibility of mRNA technology to adapt swiftly to new variants has positioned them as a frontrunner in the market. This segment is expected to continue its dominance, supported by ongoing research and development activities aimed at enhancing vaccine formulations and delivery mechanisms.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. AstraZeneca and Johnson & Johnson are key players in t

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in vacc

The market for vials used in COVID-19 vaccine distribution experienced a surge driven by the pandemic's unprecedented demand. While the initial peak has subsided, the market remains robust due to ongoing vaccination campaigns, booster shots, and the potential for future pandemics or outbreaks requiring large-scale vaccine distribution. The market's Compound Annual Growth Rate (CAGR) is estimated to be around 8% from 2025 to 2033, reflecting continued but moderated growth compared to the peak years. This sustained growth is fueled by factors such as the increasing prevalence of chronic diseases requiring preventative vaccinations, advancements in vaccine technology leading to more stable and easily-stored formulations, and the growing emphasis on pandemic preparedness globally. Key players like Corning, Schott AG, and Stevanato Group are strategically positioned to capitalize on this sustained demand by focusing on innovation in vial design and manufacturing processes, encompassing advanced materials and automation. Furthermore, the market is witnessing a shift toward sustainable and environmentally friendly vial production methods, which is shaping the future of the industry. This growth, however, is subject to certain constraints. Price fluctuations in raw materials, particularly glass, can impact profitability. Furthermore, increased regulatory scrutiny and stringent quality control measures add to the operational costs. The market is segmented based on vial type (e.g., glass, plastic), capacity, and end-user (e.g., pharmaceutical companies, hospitals). Regional variations exist, with North America and Europe currently holding significant market shares, but emerging economies in Asia-Pacific are anticipated to witness considerable growth in the coming years, driven by rising vaccination rates and increased healthcare spending. The historical period (2019-2024) reflects the dramatic shift from pre-pandemic levels to the peak demand, providing a valuable benchmark for assessing future growth trajectories. The focus will increasingly shift towards cost-effectiveness, efficiency, and sustainability in vial production and distribution.

Universal Coronavirus Vaccines Market Outlook

As per our latest research, the global Universal Coronavirus Vaccines market size was valued at USD 1.27 billion in 2024 and is projected to reach USD 7.89 billion by 2033, growing at a robust CAGR of 22.1% during the forecast period. The market’s rapid expansion is driven by the urgent need for broad-spectrum vaccines capable of addressing current and future coronavirus strains, heightened by the ongoing threat of emerging variants and pandemic preparedness initiatives worldwide.

The primary growth factor propelling the Universal Coronavirus Vaccines market is the persistent evolution and mutation of coronaviruses, including SARS-CoV-2 and its variants of concern. Traditional vaccines, while effective, often require updates to address new mutations, leading to a continuous cycle of vaccine development and deployment. In contrast, universal coronavirus vaccines are designed to elicit broad immune responses against conserved viral elements, offering protection against a wide array of coronavirus strains. This scientific innovation is attracting significant investments from both public and private sectors, with governments and global health organizations prioritizing pandemic readiness and long-term immunity solutions. The accelerated pace of research and clinical trials, supported by advanced platforms such as mRNA and viral vectors, is further fueling market growth.

Another significant driver for the Universal Coronavirus Vaccines market is the increasing collaboration among pharmaceutical companies, research institutes, and regulatory agencies. The COVID-19 pandemic underscored the necessity of swift, coordinated responses to emerging infectious diseases, leading to unprecedented partnerships and funding. These collaborations have not only expedited vaccine candidate development but have also established new regulatory pathways for rapid approval and deployment. Moreover, the global emphasis on equitable vaccine access is encouraging the development of vaccines that are effective across diverse populations, including adults, pediatrics, and geriatrics. This inclusive approach is expanding the addressable market and ensuring that universal coronavirus vaccines become a cornerstone of global immunization strategies.

Technological advancements in vaccine platforms are also playing a crucial role in the growth of the Universal Coronavirus Vaccines market. Innovations such as next-generation protein subunits, self-amplifying mRNA, and DNA-based vaccines are enabling the design of candidates with enhanced safety profiles, stability, and immunogenicity. These platforms allow for rapid adaptation to new viral threats and facilitate large-scale manufacturing and distribution. Furthermore, the integration of artificial intelligence and bioinformatics in vaccine design is accelerating the identification of conserved viral targets, optimizing antigen selection, and streamlining preclinical and clinical evaluations. As a result, the Universal Coronavirus Vaccines market is witnessing a wave of novel candidates entering the pipeline, promising to redefine the landscape of infectious disease prevention.

From a regional perspective, North America currently dominates the Universal Coronavirus Vaccines market, accounting for the largest share due to its advanced healthcare infrastructure, substantial R&D investments, and proactive government initiatives. Europe follows closely, benefiting from strong public health systems and collaborative research networks. The Asia Pacific region, however, is poised for the fastest growth, driven by increasing healthcare expenditures, rising awareness about pandemic preparedness, and expanding vaccine manufacturing capabilities. Latin America and the Middle East & Africa are also witnessing growing interest, supported by international funding and efforts to improve vaccine accessibility. As countries across all regions prioritize pandemic resilience, the Universal Coronavirus Vaccines market is set for sustained expansion in the coming years.

Vaccine Type Analysis

The Universal Coronavirus Vaccines market by vaccine type is segmented into Protein Subunit Vaccines, Viral Vector Vaccines, mRNA Vaccines, DNA Vaccines, and Others. Among these, mRNA vaccines have gained significant traction due to their proven efficacy, rapid development timelines, and adaptability to emerging viral threats. The success of mRNA-based COVID-19 vaccines ha

Vaccine Contract Manufacturing Market Outlook

According to our latest research, the global vaccine contract manufacturing market size reached USD 4.8 billion in 2024, reflecting robust demand and expansion across key regions. The market is projected to grow at a CAGR of 9.2% from 2025 to 2033, reaching an estimated USD 10.7 billion by 2033. This dynamic growth is primarily driven by the increasing outsourcing activities among vaccine developers, a surge in demand for advanced vaccine platforms, and the rising prevalence of infectious diseases globally. As per our analysis, the market is witnessing a paradigm shift as pharmaceutical and biotechnology companies increasingly rely on specialized contract manufacturing organizations (CMOs) to streamline production, reduce costs, and accelerate time-to-market for critical vaccines.

A key growth factor for the vaccine contract manufacturing market is the ongoing innovation in vaccine technologies, particularly with the emergence of mRNA and viral vector platforms. The COVID-19 pandemic has significantly accelerated the adoption of these advanced vaccine technologies, prompting both established and emerging vaccine developers to seek the expertise and infrastructure of CMOs. Contract manufacturers offer scalable production capabilities, specialized knowledge in regulatory compliance, and the flexibility to adapt to rapidly evolving vaccine formulations. The ability of CMOs to provide end-to-end services, from bulk manufacturing to fill-finish and packaging, is proving critical for companies aiming to keep pace with global vaccination campaigns and respond to emerging infectious threats.

Another driving force behind the expansion of the vaccine contract manufacturing market is the increasing complexity of vaccine development and the stringent regulatory landscape. The need for high-quality, GMP-compliant manufacturing processes has led many pharmaceutical and biotechnology companies to partner with CMOs that possess state-of-the-art facilities and deep regulatory expertise. These partnerships help vaccine developers mitigate risks, ensure product quality, and expedite regulatory approvals. Furthermore, the rising demand for pediatric, adult, and travel vaccines, coupled with the ongoing efforts to eradicate diseases such as polio, measles, and hepatitis, is fueling the need for efficient and reliable contract manufacturing solutions worldwide.

The market's growth trajectory is also shaped by the globalization of vaccine supply chains and the increasing emphasis on cost optimization. Pharmaceutical companies are increasingly outsourcing non-core activities to CMOs to focus on research and innovation while leveraging the operational efficiencies and economies of scale offered by contract manufacturers. This trend is particularly prominent among small and medium-sized enterprises (SMEs) and emerging biotechnology companies that lack the capital-intensive infrastructure required for large-scale vaccine production. As governments and international health organizations intensify efforts to enhance global immunization coverage, the demand for flexible, high-volume vaccine manufacturing solutions is expected to remain strong throughout the forecast period.

From a regional perspective, North America currently dominates the vaccine contract manufacturing market, accounting for the largest revenue share in 2024, followed by Europe and the Asia Pacific. The presence of leading pharmaceutical companies, robust healthcare infrastructure, and a favorable regulatory environment are key contributors to North America's leadership. However, the Asia Pacific region is anticipated to witness the fastest growth rate during the forecast period, driven by significant investments in biomanufacturing capacity, expanding vaccine R&D activities, and increasing government support for immunization programs. Latin America and the Middle East & Africa are also emerging as attractive markets, supported by rising healthcare expenditures and growing awareness of vaccine-preventable diseases.

Servi

The global market for Novel Coronavirus Inactivated Vaccines experienced significant growth driven by the COVID-19 pandemic. While precise market size data for 2019-2024 isn't provided, we can infer substantial expansion based on the widespread vaccine rollout. Let's assume a conservative 2024 market size of $15 billion, considering the immense global vaccination campaigns. Assuming a Compound Annual Growth Rate (CAGR) of 10% (a figure reflecting both continued demand for booster shots and potential new variants requiring updated vaccines), the market is projected to reach approximately $25 billion by 2025 and continue to grow steadily. This growth is fueled by ongoing vaccination efforts, particularly in developing nations with lower vaccination rates, and the potential for future pandemics. Factors such as government initiatives supporting vaccine development and distribution, along with the evolving understanding of COVID-19 and its long-term effects, are key drivers. However, market growth will likely moderate in the coming years as initial pandemic-related urgency subsides. Factors like waning immunity, the emergence of new variants, and the potential for alternative prophylactic measures will influence the long-term trajectory. The market is segmented by type (adult and child formulations) and application (hospitals and clinics). Leading companies involved in the production and distribution of these vaccines include Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer, Johnson & Johnson, and several prominent Chinese pharmaceutical companies. The Asia-Pacific region, particularly China and India, is expected to exhibit significant growth, driven by their large populations and increasing healthcare infrastructure. The forecast period of 2025-2033 presents opportunities and challenges. While the initial surge in demand is likely to slow, consistent demand for booster shots and potential new vaccine formulations adapted to emerging variants will sustain market growth. The continued development of more effective and convenient vaccine delivery methods, coupled with global health initiatives aiming to improve vaccination access in underserved communities, will be critical factors influencing the market trajectory. Competition among pharmaceutical companies will remain intense, necessitating innovation and strategic partnerships. Regulatory approvals and safety concerns will also play pivotal roles in shaping market dynamics throughout the forecast period. By 2033, a more mature market is anticipated, with a focus on innovation, long-term preventative strategies, and sustainable growth.

COVID-19 Vaccine Cold Chain Logistics Market Outlook

The COVID-19 Vaccine Cold Chain Logistics market size was valued at USD 10.8 billion in 2023 and is projected to reach USD 18.6 billion by 2032, growing at a CAGR of 6.2% during the forecast period. This market is primarily driven by the global efforts to ensure the effective distribution of COVID-19 vaccines, amidst an unprecedented demand for rapid and efficient vaccine delivery solutions.

The growth of this market is fueled by several critical factors. Firstly, the urgency and sheer scale of distributing COVID-19 vaccines have necessitated advancements in cold chain logistics. This sector, which ensures vaccines are stored and transported at optimal temperatures, has seen robust investments and innovation. With the vaccines requiring stringent temperature controls, from ultra-cold freezers for mRNA vaccines to standard refrigeration for others, the need for specialized logistics services has dramatically increased. This demand has caused many logistics and pharmaceutical companies to scale up their cold chain capabilities rapidly.

Another significant growth factor is the collaboration between various stakeholders, including governments, pharmaceutical companies, logistics providers, and international organizations like WHO and UNICEF. These collaborations have been pivotal in addressing the logistical challenges and ensuring that vaccines reach even the most remote locations. Governments across the globe are investing heavily in infrastructure to support cold chain logistics, recognizing it as a critical component in the fight against the pandemic. This collective effort has significantly bolstered the market.

Technological advancements are also playing a crucial role in the market's expansion. Cutting-edge technologies, such as IoT-based monitoring systems, real-time tracking, and advanced refrigeration units, have enhanced the efficiency and reliability of vaccine logistics. These innovations ensure stringent adherence to temperature requirements, reducing the likelihood of vaccine spoilage and increasing the overall reliability of vaccination campaigns. Additionally, the integration of advanced analytics and predictive tools helps in route optimization and inventory management, further streamlining the logistics process.

From a regional perspective, North America and Europe dominate the COVID-19 Vaccine Cold Chain Logistics market, owing to their robust healthcare infrastructure and significant investments in cold chain capabilities. However, Asia Pacific is emerging as a crucial market due to its large population and the extensive vaccination drives being undertaken in countries like India and China. Governments in these regions are also increasingly focusing on improving their cold chain infrastructure, presenting lucrative growth opportunities for market players.

The role of a Vaccine Transport Carrier is paramount in the cold chain logistics process, ensuring that vaccines are transported safely and efficiently from production facilities to distribution centers and ultimately to vaccination sites. These carriers are specially designed to maintain the required temperature conditions throughout the journey, preventing any compromise in vaccine efficacy. Equipped with advanced insulation materials and temperature control systems, vaccine transport carriers are integral to the logistics network, facilitating the seamless movement of vaccines across various regions. Their design and functionality are crucial in addressing the challenges posed by varying climatic conditions and long transit times, ensuring that vaccines remain viable upon arrival at their destination.

Service Type Analysis

The COVID-19 Vaccine Cold Chain Logistics market can be segmented by service type into storage, transportation, and packaging. Each of these service types plays a vital role in the effective distribution of vaccines, ensuring they remain viable from production to administration.

Storage is a critical component of cold chain logistics. It involves maintaining vaccines at specific temperatures throughout various stages of the supply chain, from manufacturing facilities to distribution centers, and finally to vaccination sites. The demand for specialized storage solutions, such as ultra-cold freezers and temperature-controlled warehouses, has surged. Companies are investing heavily in expanding their storage capacities, equipped with advanced tempera

COVID-19 Vaccines & Therapeutics Market Outlook

The global market size for COVID-19 vaccines and therapeutics was valued at USD 40 billion in 2023 and is projected to reach USD 60 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.5%. This market is driven by the ongoing need for effective vaccines and therapeutics to control the pandemic and prevent future outbreaks.

One of the primary growth factors for the COVID-19 vaccines and therapeutics market is the continuous mutation and emergence of new variants of the SARS-CoV-2 virus. The persistent evolution of the virus necessitates the development of updated vaccines and treatments, which drives demand. Furthermore, the global population's growing awareness of the importance of vaccination and the increasing government initiatives to ensure widespread vaccine coverage are significant contributors to market growth. Governments worldwide are investing heavily in vaccination programs and therapeutics to curb the spread of COVID-19, enhancing the market's expansion.

Another critical factor propelling the market is the advancements in biotechnology and pharmaceutical research. The rapid development and approval of mRNA vaccines, such as those produced by Pfizer-BioNTech and Moderna, have set a new standard in vaccine innovation. These technological advancements not only expedite the development process but also enhance the efficacy and safety profiles of vaccines and therapeutics. Companies are leveraging novel platforms and technologies to create next-generation vaccines and treatments, thereby bolstering market growth.

The increased funding and collaboration between public and private sectors also play a pivotal role in the market's growth. Governments, international organizations, and private companies are pooling resources to accelerate research and development (R&D) activities. This collaborative approach has led to the rapid production and distribution of vaccines and therapeutics on a global scale. Moreover, the establishment of public-private partnerships ensures a steady supply chain and efficient distribution networks, facilitating the market's expansion.

Regionally, North America dominates the COVID-19 vaccines and therapeutics market due to its robust healthcare infrastructure, high R&D investment, and strong regulatory framework. Europe follows closely, driven by substantial government support and a well-established pharmaceutical industry. The Asia Pacific region is expected to witness the highest growth rate over the forecast period, attributed to increasing healthcare expenditures, rising awareness, and expanding pharmaceutical manufacturing capabilities. Latin America and the Middle East & Africa regions are also contributing to market growth, albeit at a slower pace, due to ongoing vaccination campaigns and efforts to improve healthcare systems.

Product Type Analysis

The COVID-19 vaccines segment holds a significant share of the market, primarily due to the unprecedented global vaccination campaigns aimed at achieving herd immunity. Vaccines like those developed by Pfizer-BioNTech, Moderna, AstraZeneca, and Johnson & Johnson have been widely administered across the globe. The success of these vaccines has paved the way for the development of new vaccine candidates targeting various SARS-CoV-2 variants. Moreover, ongoing research into booster doses and next-generation vaccines ensures sustained demand in this segment. The development of vaccines for specific populations, such as children and immunocompromised individuals, further enhances market potential.

Antiviral drugs represent another crucial segment in the market, providing therapeutic options for individuals infected with COVID-19. Drugs like Remdesivir and Molnupiravir have been approved for emergency use and have shown efficacy in reducing viral load and improving patient outcomes. The continuous search for more effective antiviral agents and the optimization of existing treatments are expected to drive this segment's growth. Additionally, combination therapies that include antiviral drugs and other treatment modalities are being explored to enhance efficacy and reduce resistance.

Monoclonal antibodies have gained prominence as a key therapeutic option for COVID-19, especially for high-risk patients and those with severe disease. Treatments such as Regeneron's REGEN-COV and Eli Lilly's Bamlanivimab have demonstrated significant efficacy in neutralizing the virus and reducing hospitalization rates. The ongoing development of monocl

COVID-19 Therapeutics Market Outlook

According to our latest research, the global COVID-19 therapeutics market size reached USD 26.4 billion in 2024, reflecting a dynamic industry shaped by evolving virus variants, ongoing vaccination campaigns, and persistent demand for effective treatments. The market is projected to grow at a CAGR of 7.1% from 2025 to 2033, reaching an estimated USD 49.1 billion by 2033. This growth is primarily driven by the continuous emergence of new viral strains, rising investments in pharmaceutical research and development, and robust government support for pandemic preparedness and response initiatives. As per our analysis, the market’s upward trajectory underscores the critical role of therapeutics in complementing vaccination efforts and managing severe or breakthrough cases globally.

A central growth factor for the COVID-19 therapeutics market is the relentless evolution of SARS-CoV-2, which has led to the emergence of multiple variants with varying degrees of transmissibility and immune escape. These variants, including Omicron sub-lineages and others, have necessitated the development of new and more effective antiviral drugs, monoclonal antibodies, and immunomodulators. Pharmaceutical companies and research institutions are rapidly adapting their pipelines to address these challenges, resulting in a continuous influx of innovative therapeutics. Additionally, regulatory agencies have demonstrated unprecedented agility in approving emergency use authorizations and fast-tracking promising candidates, further accelerating market expansion. The demand for therapeutics remains strong, particularly for high-risk populations such as immunocompromised individuals, the elderly, and those with comorbidities.

Another significant driver is the global focus on pandemic preparedness and the strategic stockpiling of COVID-19 therapeutics by governments and health organizations. Many countries have established agreements with leading pharmaceutical companies to ensure timely access to vital medications in the event of new outbreaks or surges. This proactive approach not only stabilizes supply chains but also incentivizes ongoing research and development. Furthermore, the integration of COVID-19 therapies into standard treatment protocols for respiratory illnesses has expanded the market’s scope, as clinicians increasingly prescribe these drugs for patients presenting with severe or prolonged symptoms. The market is also benefitting from collaborations between public and private sectors, which have led to the co-development of novel formulations and combination therapies.

The widespread adoption of advanced drug delivery systems and the diversification of distribution channels have also played pivotal roles in market growth. Innovations in oral and intravenous formulations have improved patient compliance and broadened the range of therapeutic options available to healthcare providers. The expansion of hospital, retail, and online pharmacies has facilitated greater accessibility, particularly in regions with limited healthcare infrastructure. Additionally, the growing trend toward homecare and outpatient management of mild-to-moderate COVID-19 cases has stimulated demand for user-friendly and easily administered therapeutics. This shift is supported by telemedicine platforms and digital health tools that enable remote monitoring and prescription fulfillment, further enhancing the market’s reach.

Regionally, North America continues to dominate the COVID-19 therapeutics market, accounting for the largest revenue share in 2024, followed closely by Europe and the Asia Pacific. The United States, in particular, benefits from a robust pharmaceutical industry, substantial government funding, and high rates of therapeutic adoption. Europe’s market is driven by strong regulatory frameworks and cross-border collaborations, while the Asia Pacific region is experiencing rapid growth due to rising healthcare investments and increasing disease awareness. Latin America and the Middle East & Africa are emerging as important markets, supported by international aid and expanding healthcare infrastructure. Each region faces unique challenges and opportunities, shaping the overall landscape of COVID-19 therapeutics.

Drug Class Analysis

The COVID-19 therapeutics market is segmented by drug class into antiviral drugs, immunomodulators, monoclonal antibodies, corticosteroids, and others. Among these, antiviral d

Explore the evolving market for approved COVID-19 vaccines. This analysis projects market size, CAGR, and regional shares, highlighting key drivers, restraints, and leading companies like Moderna, Pfizer, and Johnson & Johnson. Discover future trends in this dynamic sector.

The global market for butyl rubber stoppers used in COVID-19 vaccines experienced significant growth driven by the pandemic's unprecedented demand. While precise figures for the market size in 2025 are unavailable, considering a CAGR of 5% from a presumed pre-pandemic market size (extrapolated from industry reports and general pharmaceutical packaging growth), and a substantial boost during the vaccine rollout, a reasonable estimation for the 2025 market size is approximately $500 million. This surge was fueled by the massive production and distribution of COVID-19 vaccines globally, necessitating large quantities of high-quality, reliable stoppers to maintain vaccine integrity. The market segmentation reveals a preference for butyl rubber and its variations (Halogenated Butyl Rubber and Precrosslinked Terpolybutyl Rubber) due to their superior sealing properties, inertness, and compatibility with various vaccine formulations. The dominant application remains inactivated vaccines, although the usage in adenovirus vector and recombinant protein vaccines is also substantial and growing. Key players like West Pharma and Datwyler, alongside numerous regional manufacturers, contributed to meeting this high demand. Post-pandemic, the market is expected to stabilize, though continued demand for various vaccines (including influenza and other emerging infectious diseases) will ensure sustained growth. While the exceptional surge witnessed during the height of the pandemic may not be replicated, the projected CAGR of 5% from 2025-2033 suggests a continued expansion, reaching an estimated market size of around $820 million by 2033. Factors like increasing vaccination rates globally, advancements in vaccine technology, and the ongoing need for efficient vaccine storage and transportation will support this growth. However, factors like fluctuating raw material prices and increasing competition among manufacturers could act as restraints on market growth. The regional distribution likely reflects a strong presence in North America and Europe initially, followed by a growing demand in the Asia-Pacific region driven by increasing manufacturing and vaccination efforts.

Viral Vector Vaccines Market Outlook

The global viral vector vaccines market size is projected to grow significantly, with a market size of $2.5 billion in 2023 and anticipated to reach $10.8 billion by 2032, reflecting a compound annual growth rate (CAGR) of 17.8%. The primary growth factors driving this market include the increasing prevalence of infectious diseases, advancements in gene therapy, and the pivotal role viral vector vaccines play in developing vaccines for newly emerging diseases like COVID-19.

The growth of the viral vector vaccines market is majorly driven by technological advancements in the field of biotechnology and genetic engineering. The ability to manipulate viral vectors for specific therapeutic purposes has revolutionized the development of vaccines and treatments for various diseases. The increasing investment by pharmaceutical companies in research and development of viral vector vaccines is also a major contributor to market growth. Furthermore, a growing number of clinical trials demonstrating the efficacy and safety of these vaccines is expected to bolster market expansion.

Another key growth factor is the rising incidence of infectious diseases, which has highlighted the need for effective vaccination strategies. The ongoing COVID-19 pandemic has particularly underscored the importance of rapid vaccine development and deployment. Viral vector vaccines, such as those developed by AstraZeneca and Johnson & Johnson, have proven to be highly effective against COVID-19, thereby increasing their acceptance and adoption globally. This scenario is likely to persist, with the market witnessing continuous growth due to the necessity of addressing other emerging infectious diseases.

Moreover, the application of viral vector vaccines in gene therapy for treating genetic disorders represents a significant breakthrough in modern medicine. Diseases that were previously considered untreatable, such as certain genetic disorders and cancers, are now being targeted using viral vector vaccines. This expanding application field is expected to drive market growth in the upcoming years. Additionally, government support and favorable regulatory frameworks are playing crucial roles in accelerating the approval and commercialization of new viral vector vaccines, further propelling market growth.

Regionally, North America currently holds the largest share of the viral vector vaccines market, attributed to the presence of leading pharmaceutical companies, advanced healthcare infrastructure, and substantial government funding for research and development. However, the Asia Pacific region is expected to witness the highest growth rate, driven by increasing healthcare investments, rising prevalence of infectious diseases, and growing awareness about advanced therapeutic options. Europe also stands as a significant market due to its strong biomedical research landscape and supportive regulatory environment.

Type Analysis

The viral vector vaccines market is segmented by type into adenoviral vectors, lentiviral vectors, retroviral vectors, and others. Adenoviral vectors are currently the most widely used due to their ability to induce strong immune responses and the extensive research supporting their efficacy and safety. Adenoviral vector-based vaccines have been prominently used in the fight against COVID-19, with vaccines such as AstraZeneca’s Vaxzevria and Johnson & Johnson’s Janssen gaining widespread use. The success of these vaccines has set a precedent for future developments in this vector type, ensuring continued investment and research.

Lentiviral vectors are gaining traction, particularly in gene therapy applications. Their ability to integrate into the host genome makes them suitable for long-term expression of therapeutic genes, which is crucial for treating chronic genetic disorders. The flexibility and efficiency of lentiviral vectors in delivering genes into non-dividing cells broaden their application scope, making them a preferred choice for therapies targeting genetic disorders and certain types of cancers. Continued advancements in lentiviral vector technology are expected to contribute significantly to market growth.

Retroviral vectors, although less commonly used compared to adenoviral and lentiviral vectors, hold significant potential in specific therapeutic areas. They are particularly useful in gene therapy fo

The COVID-19 vaccine development tools market experienced significant growth during the pandemic's peak, driven by the urgent need for rapid vaccine development and deployment. The market encompasses a broad range of technologies and services, including cell culture media, reagents, analytical instruments, and contract research organizations (CROs). The high demand for efficient and scalable vaccine production processes led to substantial investments in research and development, accelerating innovation in areas such as mRNA technology and viral vector platforms. Major players, including Thermo Fisher Scientific, Pfizer, and others listed, benefited from this surge in demand, solidifying their market positions. While the immediate crisis has subsided, the market continues to grow, albeit at a more moderate pace. This sustained growth is fueled by ongoing research into variants, the development of next-generation vaccines, and preparedness for future pandemics. The market is also witnessing increasing adoption of advanced technologies like AI and machine learning for vaccine development and optimization. Continued investment in manufacturing capabilities, coupled with evolving regulatory landscapes and a focus on global vaccine equity, will shape the market's trajectory in the coming years. The market segmentation is likely diverse, encompassing various tools based on technology (mRNA, viral vectors, protein-based), application (research, development, manufacturing), and end-user (pharmaceutical companies, research institutions, CROs). Regional variations exist, with North America and Europe initially holding substantial market share due to advanced research infrastructure and strong pharmaceutical industries. However, growth in other regions is expected as investments in vaccine development and manufacturing infrastructure expand globally. Factors such as regulatory approvals, pricing pressures, and the emergence of alternative technologies will influence market dynamics. The long-term outlook remains positive, driven by the need for robust pandemic preparedness and the ongoing evolution of vaccine technology. Continuous innovations in vaccine development tools promise to enhance efficiency, speed, and affordability, making vaccines more accessible globally.

Circular RNA Vaccine Platforms Market Outlook

As per our latest research, the global Circular RNA Vaccine Platforms market size reached USD 1.12 billion in 2024, exhibiting robust growth momentum driven by a surge in RNA-based therapeutics and vaccine innovation. The market is projected to expand at a remarkable CAGR of 19.7% from 2025 to 2033, with the forecasted market size expected to reach USD 5.51 billion by 2033. This rapid expansion is primarily fueled by advances in RNA technology, rising investments in vaccine development, and the increasing prevalence of infectious and chronic diseases globally.

One of the primary growth factors for the Circular RNA Vaccine Platforms market is the significant technological advancement in RNA biology and vaccine delivery systems. Circular RNA (circRNA) molecules, characterized by their covalently closed loop structures, offer increased stability and translational efficacy compared to linear RNA. These attributes make them highly attractive for vaccine development, particularly in the context of rapidly mutating pathogens and emerging infectious diseases. The ability of circRNA vaccines to induce robust and durable immune responses while minimizing the risk of degradation has captured the attention of pharmaceutical and biotechnology companies. Furthermore, the success of mRNA vaccines during the COVID-19 pandemic has accelerated research and adoption of next-generation RNA platforms, including circRNA, thereby fostering market growth.

Another critical driver for the Circular RNA Vaccine Platforms market is the increasing prevalence of infectious diseases and cancer worldwide. The global burden of diseases such as influenza, HIV, hepatitis, and various cancers has underscored the need for innovative and effective vaccine solutions. Circular RNA vaccines are being actively explored for both prophylactic and therapeutic applications, offering the potential to address unmet medical needs across a broad spectrum of indications. The flexibility of circRNA technology allows for rapid antigen design and production, enabling swift responses to emerging health threats. Additionally, favorable regulatory pathways and growing public-private partnerships are supporting accelerated clinical development and commercialization of circRNA-based vaccines, further propelling market expansion.

In addition to technological advancements and disease prevalence, increasing investments from both public and private sectors are catalyzing the growth of the Circular RNA Vaccine Platforms market. Major pharmaceutical companies, venture capitalists, and government agencies are injecting substantial funds into RNA research, manufacturing infrastructure, and clinical trials. This influx of capital is enabling the development of scalable and cost-effective manufacturing processes, facilitating broader access to circRNA vaccines. Moreover, collaborations between academic institutions and industry players are fostering innovation, knowledge sharing, and the translation of scientific discoveries into commercial products. As the competitive landscape intensifies, companies are focusing on strategic alliances, licensing agreements, and mergers to strengthen their market positions and accelerate product pipelines.

From a regional perspective, North America currently dominates the Circular RNA Vaccine Platforms market, accounting for the largest revenue share in 2024. This leadership is attributed to the presence of leading biotechnology firms, advanced research infrastructure, and supportive regulatory frameworks. Europe follows closely, benefiting from strong government support for biotechnology innovation and a robust network of academic research institutes. The Asia Pacific region is emerging as a significant growth engine, driven by rising healthcare investments, a large patient population, and increasing adoption of advanced vaccine technologies. Latin America and the Middle East & Africa are also witnessing gradual growth, supported by improving healthcare access and growing awareness of RNA-based therapeutics.

Product Type Analysis

The Circular RNA Vaccine Platforms market by product type is segmented into Therapeutic Vaccines and Prophylactic Vaccines. Therapeutic vaccines are gaining significant traction due to their potential to treat existing diseases, particularly in oncology and chronic infectious diseases. These vaccines are

The market for vials used in COVID-19 vaccine distribution experienced significant growth during the pandemic's peak and continues to evolve. While precise figures for market size and CAGR are unavailable, industry analysis suggests a substantial market value, likely in the billions of dollars, driven by the unprecedented demand for vaccine storage and distribution. The high volume of vaccines produced and administered globally necessitated a massive increase in vial production, propelling significant growth. Key drivers included the urgent need for safe and effective vaccine delivery, stringent regulatory requirements for pharmaceutical packaging, and the global expansion of vaccination programs. Trends include increased adoption of advanced vial materials (like those offering enhanced barrier properties and improved stability), a shift towards more sustainable and eco-friendly manufacturing processes, and growing demand for specialized vials designed to accommodate specific vaccine formulations. Restraints could include potential supply chain disruptions, fluctuations in raw material prices, and the overall stabilization of vaccine demand post-pandemic. Leading companies like Corning, Schott AG, and others played a crucial role in meeting the global demand, showcasing their capacity for rapid scaling and technological innovation. The market's future growth will depend on factors such as the emergence of new vaccines, booster campaigns, and the ongoing need for cold-chain logistics. While the initial surge has likely subsided, a steady, albeit smaller, demand persists due to ongoing vaccination efforts and the potential for future pandemic preparedness. The market segmentation is expected to be broad, encompassing various vial types (glass, plastic, pre-filled syringes), sizes, and closure systems. Regional performance is likely varied, with developed nations initially exhibiting higher demand given the initial rollout of vaccines. However, developing regions are increasingly adopting more vaccination programs, creating ongoing opportunities. Future projections suggest a period of consolidation and moderate growth, with continued innovation and adaptation within the industry shaping its trajectory. The market will likely see a focus on efficiency, cost reduction, and improved sustainability in the coming years.

Snapshot img { margin: 10px !important; } This pipeline analysis report provides detailed insights into the clinical trials landscape of COVID-19 therapeutics, including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration (RoA), target, mechanism of action (MoA), and therapeutic modalities. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline molecules for COVID-19 including AbbVie Inc., AIM ImmunoTech Inc., Ansun BioPharma, APEIRON Biologics AG, Ascletis Pharma Inc., Blade Therapeutics Inc., Can-Fite BioPharma Ltd., CanSino Biologics Inc., Clover Biopharmaceuticals, F. Hoffmann-La Roche Ltd., FUJIFILM Corp., Gilead Sciences Inc., IMV Inc., InflaRx GmbH, Inovio Pharmaceuticals Inc., and Johnson & Johnson Services Inc.

Overview of Therapeutic Pipeline for COVID-19

The COVID-19 pandemic started in China in the last quarter of 2019 and spread globally by early 2020. Globally, the incidence and prevalence of COVID-19 are increasing aggressively. According to the Worldometers.info report, updated on April 13, 2020, the number of COVID-19 cases reported was 1,862,254, out of which 6.17% of the people have lost their lives, and about 23.18% people have been recovered globally.

Coronavirus disease (COVID-19) is infectious and is caused by a new coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the people affected with COVID-19 experience mild-to-moderate respiratory illness and recover without requiring special treatment. However, older people and people with certain medical conditions, including cardiovascular diseases, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness. Currently, there are no specific vaccines or treatments for COVID-19. However, owing to the above-mentioned factors, many ongoing clinical trials are evaluating potential treatments, especially target molecules for the immune system. Over 26% of the molecules in the pipeline are currently in the pre-clinical stages.

Companies covered

Several companies are involved in the development of pipeline molecules for COVID-19. In addition to the companies, major institutes, universities, and hospitals are also conducting studies on COVID-19. Moreover, companies are collaborating with institutions such as the US Department of Health & Human Services and the University of British Columbia to use the available technologies properly for the further development and commercialization of molecules.

The report covers detailed information on several companies actively involved in the development of molecules for COVID-19 including -

AbbVie Inc.
AIM ImmunoTech Inc.
Ansun BioPharma
APEIRON Biologics AG
Ascletis Pharma Inc.
Blade Therapeutics Inc.
Can-Fite BioPharma Ltd.
CanSino Biologics Inc.
Clover Biopharmaceuticals
F. Hoffmann-La Roche Ltd.
FUJIFILM Corp.
Gilead Sciences Inc.
IMV Inc.
InflaRx GmbH
Inovio Pharmaceuticals Inc.
Johnson & Johnson Services Inc.
Mallinckrodt Plc
Moderna Inc.
NeuroRx Inc.
Novavax Inc.
OncoImmune Inc.
OyaGen Inc.
Pulmotect Inc.
RedHill Biopharma Ltd.
Regeneron Pharmaceuticals Inc.
Sanofi
SLA Pharma AG
Sorrento Therapeutics Inc.
Swedish Orphan Biovitrum AB
Symvivo Corp.
Takeda Pharmaceutical Co.
Tonix Pharmaceuticals Holding Corp.
Vanda Pharmaceuticals Inc.
Vaxart Inc.

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Route of Administration

Oral
Intravenous
Nasal
Intradermal
Intramuscular
Unknown

Most of the pipeline molecules for COVID-19 treatment are being developed for oral administration. Additionally, companies and institutions are also focusing on developing drugs that can be delivered through the subcutis (intravenous RoA).

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Therapy

Monotherapy
Combination therapy

Monotherapy uses a single drug to treat a disorder. Over 64% of the molecules that are currently in the pipeline to treat COVID-19 are being developed as monotherapy drugs.

COVID-19 - Pipeline Analysis: Key Highlights of the Report

What are the therapy molecules used in the various development stages of COVID-19?
What are the companies that are currently involved in the development of therapeutic molecules for COVID-19?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Context

COVID has changed our lives. With millions affected this has been an time when many companies had to change the wa,y they do business to survive. This pandemic has in a way boosted the India Pharma - with India developing two vaccines to fight this Pandemic.

Content

This dataset contains the share price of Bharat Biotech since 2000- India's indigenous COVID-19 vaccine COVAXIN® manufacturer, developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).

Acknowledgements

This data has been collected from Yahoo Finance(https://finance.yahoo.com/quote/BIBCL.BO/history?p=BIBCL.BO)